文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

[177Lu]Lu-DOTAGA-FAPi二聚体在治疗选择有限的转移性乳腺癌患者中的治疗潜力:疗效与安全性评估

Therapeutic potential of [177Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-11-07

这项回顾性研究评估了[177Lu]Lu-DOTAGA.FAPi二聚体放射性核素治疗在19例经[68Ga]Ga-DOTA.SA.FAPi PET/CT确认FAP表达的晚期转移性乳腺癌患者中的安全性和有效性,患者平均年龄44.6±10.7岁,中位随访14个月。结果显示临床疾病控制率95%、客观缓解率84%,中位总生存12个月、中位无进展生存8.5个月,未观察到3或4级不良事件。作者认为该治疗耐受良好、安全有效,但需进一步研究和更长随访以评估长期结局。

要点

  • 19例晚期转移性乳腺癌患者接受[177Lu]Lu-DOTAGA.FAPi二聚体治疗,中位3个周期,中位随访14个月。
  • 临床疾病控制率95%、客观缓解率84%,中位总生存12个月、中位无进展生存8.5个月。
  • 未观察到3或4级血液学、肾脏、肝脏毒性、电解质紊乱或不良事件。

核心结论

  • 作者认为[177Lu]Lu-DOTAGA.FAPi二聚体治疗对终末期转移性乳腺癌患者耐受良好、安全且有效,表现为高疾病控制率、良好缓解结局和可接受的安全性。
  • 作者指出需要进一步研究和更长随访以评估长期结局并验证这些发现。

研究设计与样本

  • 回顾性研究,于2020年11月至2023年3月以同情用药方式对经[68Ga]Ga-DOTA.SA.FAPi PET/CT确认FAP表达的晚期乳腺癌患者给予[177Lu]Lu-DOTAGA.FAPi二聚体放射性核素治疗。
  • 共纳入19例转移性乳腺癌患者(18例女性、1例男性),平均年龄44.6±10.7岁,均为重度经治患者。
  • 治疗间隔8至12周,中位随访14个月;主要终点为基于PERCIST标准的[68Ga]Ga-DOTA.SA.FAPi PET/CT分子缓解评估,次要终点包括总生存、无进展生存、临床缓解评估及基于CTCAE v5.0的安全性评价。

主要发现

  • 共给予65个周期,平均累积活度19±5.7 GBq(510±154 mCi),范围11至33.3 GBq(300至900 mCi);周期数2至6个,中位3个。
  • 周期分布为:2个周期5例、3个周期9例、4个周期1例、6个周期4例。
  • 病理类型为浸润性/浸润性导管癌94.7%、浸润性小叶癌5.3%;全部患者有骨转移,其中5例合并肝受累、7例有脑转移。
  • [68Ga]Ga-DOTA.SA.FAPi PET/CT评估的16例中,25%达部分缓解,37.5%出现疾病进展。
  • 按VAS缓解标准,完全缓解26.3%、部分缓解15.7%、微小缓解42%、疾病稳定11%、无缓解5%;临床疾病控制率95%,临床客观缓解率84%。

关键数值与推荐

  • 分子缓解评估采用PERCIST标准,基于[68Ga]Ga-DOTA.SA.FAPi PET/CT。
  • 安全性评价采用CTCAE v5.0指南。
  • 临床缓解评估采用VAS缓解标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需要进一步研究和更长随访以评估长期结局并验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The upregulation of fibroblast activation protein (FAP) expression has been observed in various cancers, including metastatic breast carcinoma, prompting research into small molecule inhibitors for both diagnostic and therapeutic purposes. While the diagnostic value of PET/CT imaging using 68 Ga- or 18F-labelled FAPi-monomers in breast cancer diagnosis is well-established, there is a significant need for therapeutic analogs. This retrospective study aimed to assess the safety and effectiveness of [177Lu]Lu-DOTAGA.FAPi dimer radionuclide therapy in patients with advanced-stage breast cancer who had previously undergone [68 Ga]Ga-DOTA.SA.FAPi PET/CT scans to confirm the expression of FAP. MATERIALS AND METHODS: Between November 2020 and March 2023, a compassionate treatment approach was utilized to administer [177Lu]Lu-DOTAGA.FAPi dimer radionuclide therapy to heavily pretreated patients with advanced breast cancer. Nineteen patients (18 females, 1 male) with metastatic breast cancer participated in the study, with an average age of 44.6 ± 10.7 years. The therapy was administered at intervals of 8 to 12 weeks, and the median follow-up duration was 14 months. The primary objective of the study was to assess molecular response using [68 Ga]Ga-DOTA.SA.FAPi PET/CT scans, with response evaluation based on the PERCIST criteria. Secondary endpoints included overall survival (OS), progression-free survival (PFS), clinical response assessment, and safety evaluation using CTCAE v5.0 guidelines. RESULTS: A total of 65 cycles were administered, with a mean cumulative activity of 19 ± 5.7 GBq (510 ± 154 mCi) ranging from 11 to 33.3 GBq (300 to 900 mCi) of [177Lu]Lu-DOTAGA.FAPi dimer. The number of cycles ranged from 2 to 6, with a median of 3 cycles. The treatment protocol consisted of different numbers of cycles administered to the patients: specifically, two cycles were given to five patients, three cycles to nine patients, four cycles to one patient, and six cycles to four patients. Most patients had invasive/infiltrative ductal carcinoma (94.7%), while a small percentage had invasive lobular carcinoma (5.3%). All patients had bone metastases, and five of them also had liver involvement, while seven had brain metastases. Response assessment using [68 Ga]Ga-DOTA.SA.FAPi PET/CT scans showed that 25% of the 16 patients evaluated had partial remission, while 37.5% exhibited disease progression. According to the VAS response criteria, 26.3% achieved complete response, 15.7% had partial response, 42% showed minimal response, 11% had stable disease, and 5% had no response. The clinical disease control rate was promising, with 95% of patients achieving disease control. The clinical objective response rate was 84%. The median follow-up period was 14 months. At the time of analysis, the median overall survival was 12 months, and the median progression-free survival was 8.5 months. Notably, no severe hematological, renal, or hepatic toxicities, electrolyte imbalances, or adverse events of grade 3 or 4 were observed during the study. CONCLUSION: The findings suggest that [177Lu]Lu-DOTAGA.FAPi dimer therapy is well-tolerated, safe, and effective for treating end-stage metastatic breast cancer patients. [177Lu]Lu-DOTAGA.FAPi dimer treatment demonstrated promising efficacy in patients with advanced breast cancer, as indicated by high disease control rates, favorable response outcomes, and acceptable safety profile. Further research and longer follow-up are warranted to assess long-term outcomes and validate these findings.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Yadav MP, Ballal S, Martin M, et al. Therapeutic potential of [177Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment. Eur J Nucl Med Mol Imaging. 2023. PMID: 37932560. doi:10.1007/s00259-023-06482-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。